TCR2 Therapeutics (TCRR) Prices 4.59M Share Common Offering at $30.50/Sh

TCR² Therapeutics Inc. (NASDAQ: TCRR) today announced the pricing of an underwritten public offering of 4,590,164 shares of its common stock at a public offering price of $30.50 per share. TCR² also granted the underwriters a 30-day option to purchase up to an additional 688,524 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $140.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by TCR². The offering is expected to close on or about January 22, 2021, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Jefferies, Piper Sandler and BMO Capital Markets are acting as joint book-running managers for the offering.

TCR² intends to use the net proceeds of the offering to advance its clinical and earlier stage programs and for research and development, working capital and general corporate purposes.

The securities described may be offered pursuant to a shelf registration statement on Form S-3 (File No. 333-236965), including a base prospectus that was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2020. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to, and describing the terms of, this offering was filed with the SEC on January 19, 2021.

You May Also Be Interested In

• OceanaGold to acquire Ausgold in a deal valued at A$776M
• Silence Therapeutics closes $201M public offering of ADSs
• Realty Income closes $1B convertible notes offering